These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 12034048

  • 1. Induction of blood 2',5'-oligoadenylate synthetase activity in mice by gastric administration of ovine IFN-tau.
    Nakajima A, Sokawa Y.
    J Interferon Cytokine Res; 2002 Mar; 22(3):397-402. PubMed ID: 12034048
    [Abstract] [Full Text] [Related]

  • 2. Oral feeding of interferon tau can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis.
    Soos JM, Mujtaba MG, Subramaniam PS, Streit WJ, Johnson HM.
    J Neuroimmunol; 1997 May; 75(1-2):43-50. PubMed ID: 9143236
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic effect of recombinant human IFN-alpha, continuously released from a matrix prepared from a polyglycerol ester of fatty acids, on 2',5'-oligoadenylate synthetase activity in murine liver.
    Yamagata Y, Yuasa Y, Yamamoto K, Okamoto K, Igari Y, Iga K, Ogawa Y.
    J Interferon Cytokine Res; 2000 Feb; 20(2):153-60. PubMed ID: 10714550
    [Abstract] [Full Text] [Related]

  • 4. In vitro and in vivo 2',5'-oligoadenylate synthetase activity induced by recombinant DNA-derived bovine interferon alpha I1 in bovine alveolar macrophages and blood mononuclear cells.
    Holland SP, Fulton RW, Short EC, Wyckoff JH, Fox JC.
    Am J Vet Res; 1991 Nov; 52(11):1779-83. PubMed ID: 1664669
    [Abstract] [Full Text] [Related]

  • 5. Basis for dosing time-dependent changes in the antiviral activity of interferon-alpha in mice.
    Ohdo S, Wang DS, Koyanagi S, Takane H, Inoue K, Aramaki H, Yukawa E, Higuchi S.
    J Pharmacol Exp Ther; 2000 Aug; 294(2):488-93. PubMed ID: 10900223
    [Abstract] [Full Text] [Related]

  • 6. Effect of oromucosal administration of IFN-alpha on allergic sensitization and the hypersensitive inflammatory response in animals sensitized to ragweed pollen.
    Meritet JF, Maury C, Tovey MG.
    J Interferon Cytokine Res; 2001 Aug; 21(8):583-93. PubMed ID: 11559436
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of the estrous cycle, pregnancy, and interferon tau on 2',5'-oligoadenylate synthetase expression in the ovine uterus.
    Johnson GA, Stewart MD, Gray CA, Choi Y, Burghardt RC, Yu-Lee LY, Bazer FW, Spencer TE.
    Biol Reprod; 2001 May; 64(5):1392-9. PubMed ID: 11319143
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Interferon and 2',5'-oligo(A) synthetase activities in serum and blood mononuclear leukocytes of cattle after injection of bovine interferon-alpha 1.
    Perino LJ, Short EC, Burge LJ, Winter DA, Fulton RW.
    Am J Vet Res; 1990 Jun; 51(6):886-92. PubMed ID: 1695068
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of 2,5-oligoadenylate synthetase and protein kinase activities in clinical studies of larifan and recombinant interferon alpha in volunteers].
    Sokolova TM, Nosik NN, Lopatina OA, Krylov VF.
    Antibiot Khimioter; 1991 Jul; 36(7):42-5. PubMed ID: 1953190
    [Abstract] [Full Text] [Related]

  • 14. Monitoring of interferon treatment in patients with renal cell carcinoma and bladder carcinoma by oligo-A synthetase assay and determination of immunological parameters.
    Grups JW, Komprecht B.
    J Biol Regul Homeost Agents; 1989 Jul; 3(3):98-101. PubMed ID: 2516404
    [Abstract] [Full Text] [Related]

  • 15. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
    Giosuè S, Casarini M, Ameglio F, Alemanno L, Saltini C, Bisetti A.
    Eur Respir J; 1996 Jan; 9(1):42-6. PubMed ID: 8834332
    [Abstract] [Full Text] [Related]

  • 16. Effects of oral administration of interferon-alpha on antibody production in mice with induced tolerance.
    Takayama S, Iwaki K, Nishida Y, Tanaka M, Fujii M, Ohashi K, Ikeda M, Kurimoto M.
    J Interferon Cytokine Res; 1999 Aug; 19(8):895-900. PubMed ID: 10476935
    [Abstract] [Full Text] [Related]

  • 17. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
    Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, Teitelbaum AP, Smalley RV, Borden EC.
    J Natl Cancer Inst; 1989 Jul 19; 81(14):1061-8. PubMed ID: 2472488
    [Abstract] [Full Text] [Related]

  • 18. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH, Storer B, Witt PL, Nelson B, Brown RR, Horisberger M, Grossberg S, Borden EC.
    Cancer Res; 1990 Aug 01; 50(15):4588-94. PubMed ID: 2114942
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2',5'-oligoadenylate synthetase.
    Rosenblum MG, Maxwell BL, Talpaz M, Kelleher PJ, McCredie KB, Gutterman JU.
    Cancer Res; 1986 Sep 01; 46(9):4848-52. PubMed ID: 2942242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.